TY - JOUR
T1 - Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy
AU - Di Perri, Giovanni
AU - Vento, Sandro
AU - Mazzi, Romualdo
AU - Bonora, Stefano
AU - Bonora, Adiriana
AU - Trevenzoli, Marco
AU - Allegranzi, Benedetta
AU - Carretta, Giovanni
AU - Lanzafame, Massimiliano
AU - Pizzighella, Sergio
AU - Concia, Ercole
PY - 1999/11
Y1 - 1999/11
N2 - Objectives: To see whether in severely immunosuppressed AIDS patients (with prior Cytomegalovirus retinal disease) who have significant increases in CD4+ lymphocytes following the initiation of highly active antiretroviral therapy (HAART) anti-Cytomegalovirus (CMV) maintenance therapy can be withdrawn with no subsequent progression of CMV retinitis. Methods: Eight patients with AIDS and one or more previous episodes of CMV retinitis interrupted anti-CMV maintenance therapy following the successful beginning of HAART. CD4 cell counts and HIV-RNA were monitored monthly while measurement of CMV antigenemia and ophthalmoscopy were carried every 2 weeks thereafter. Results: The HAART recipients in whom anti-CMV maintenance therapy had been interrupted had measureable increases of CD4+ T lymphocytes, substantial control of both HIV-RNA and CMV viraemia and did not show recurrence of retinitis during a mean follow-up of 98.4 weeks (range 78-120, SD 15.2). Conclusions: Anti-CMV maintenance therapy can be interrupted with no subsequent progression of retinal damage over a long time in patients with AIDS who successfully respond to HAART with a significant increase in CD4 cell count. (C) 1999 The British Infection Society.
AB - Objectives: To see whether in severely immunosuppressed AIDS patients (with prior Cytomegalovirus retinal disease) who have significant increases in CD4+ lymphocytes following the initiation of highly active antiretroviral therapy (HAART) anti-Cytomegalovirus (CMV) maintenance therapy can be withdrawn with no subsequent progression of CMV retinitis. Methods: Eight patients with AIDS and one or more previous episodes of CMV retinitis interrupted anti-CMV maintenance therapy following the successful beginning of HAART. CD4 cell counts and HIV-RNA were monitored monthly while measurement of CMV antigenemia and ophthalmoscopy were carried every 2 weeks thereafter. Results: The HAART recipients in whom anti-CMV maintenance therapy had been interrupted had measureable increases of CD4+ T lymphocytes, substantial control of both HIV-RNA and CMV viraemia and did not show recurrence of retinitis during a mean follow-up of 98.4 weeks (range 78-120, SD 15.2). Conclusions: Anti-CMV maintenance therapy can be interrupted with no subsequent progression of retinal damage over a long time in patients with AIDS who successfully respond to HAART with a significant increase in CD4 cell count. (C) 1999 The British Infection Society.
UR - http://www.scopus.com/inward/record.url?scp=12944281749&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12944281749&partnerID=8YFLogxK
U2 - 10.1016/S0163-4453(99)90048-8
DO - 10.1016/S0163-4453(99)90048-8
M3 - Article
C2 - 10714794
AN - SCOPUS:12944281749
VL - 39
SP - 193
EP - 197
JO - Journal of Infection
JF - Journal of Infection
SN - 0163-4453
IS - 3
ER -